https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-12-10 13:09:112016-11-28 13:35:36SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-12-10 11:10:232016-11-28 13:36:23Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-12-03 13:10:542016-11-28 13:36:48SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology’s 49th Annual Meeting
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-11-29 13:11:282016-11-28 13:37:11Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-10-25 13:13:082016-11-28 13:39:00Data Support use of SuperGen’s CLIMB Technology in Lead Development and Optimization
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2007-10-25 12:13:392016-11-28 13:39:21Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents
